CD8A and myeloid sarcoma: CD49/CD29 was significantly reduced on the EM CD8+ T cells of the CFS/ME patients in comparison to the nonfatigued controls, while in the MS patients, CD49d/CD29 was significantly elevated in the naïve and EMRA CD8+ T cells in comparison to the nonfatigued controls (Figure 2(a)).